Expression of hepatitis B surface antigen gene (HBsAg) in Laminaria japonica (Laminariales, Phaeophyta)

A transformation model for Laminaria japonica was established from 1993 to 1998, on the basis of which the transgenic kelp with heterologous gene encoding hepatitis B surface antigen (HBsAg) was obtained by using the micro-particle bombardment transformation method. Results of quantitative ELISA showed that HBsAg in transgenic kelp was 0.529 mug/mg soluble proteins on average and the highest value was 2.497 mug/mg, implying that recombinant HBsAg had natural epitope. Further support for the integration of HBsAg gene into kelp genome was obtained by PCR-Southern and total DNA hybridization. Prospect of kelp bio-reactor producing high value materials such as edible HBV vaccine was discussed as well.

Transgenic lettuce seedlings carrying hepatitis B virus antigen HBsAg

The obtainment of transgenic edible plants carrying recombinant antigens is a desired issue in search for economic alternatives viewing vaccine production. Here we report a strategy for genetic transformation of lettuce plants (Lactuca sativa L.) using the surface antigen HBsAg of hepatitis B virus. Transgenic lettuce seedlings were obtained through the application of a regulated balance of plant growth regulators. Genetic transformation process was acquired by cocultivation of cotyledons with Agrobacterium tumefaciens harboring the recombinant plasmid. It is the first description of a lettuce Brazilian variety Vitória de Verão genetically modified.

Performance of HBsAg point-of-care tests for detection of diagnostic escape-variants in clinical samples

BACKGROUND Hepatitis B viruses (HBV) harboring mutations in the a-determinant of the Hepatitis B surface antigen (HBsAg) are associated with reduced reactivity of HBsAg assays. OBJECTIVES To evaluate the sensitivity and specificity of three HBsAg point-of-care tests for the detection of HBsAg of viruses harboring HBsAg mutations. STUDY DESIGN A selection of 50 clinical plasma samples containing HBV with HBsAg mutations was used to evaluate the performance of three HBsAg point-of-care tests (Vikia(®), bioMérieux, Marcy-L'Étoile, France. Alere Determine HBsAg™, Iverness Biomedical Innovations, Köln, Germany. Quick Profile™, LumiQuick Diagnostics, California, USA) and compared to the ARCHITECT HBsAg Qualitative(®) assay (Abbott Laboratories, Sligo, Ireland). RESULTS The sensitivity of the point-of-care tests ranged from 98% to 100%. The only false-negative result occurred using the Quick Profile™ assay with a virus harboring a D144A mutation. CONCLUSIONS The evaluated point-of-care tests revealed an excellent sensitivity in detecting HBV samples harboring HBsAg mutations.

Prevalence of HBsAg mutants and impact of hepatitis B infant immunisation in four Pacific Island countries

The prevalence rate of hepatitis B virus (HBV) infection in Pacific Island countries is amongst the highest in the world. Hepatitis B immunisation has been incorporated into national programmes at various times, often with erratic supply and coverage, until a regionally co-ordinated programme, which commenced in 1995 ensured adequate supply. The effectiveness of these programmes was recently evaluated in four countries, Vanuatu and Fiji in Melanesia, Tonga in Polynesia and Kiribati in Micronesia. That evaluation established that the programmes had a substantial beneficial impact in preventing chronic hepatitis B infection [Vaccine 18 (2000) 3059]. Several studies of hepatitis B vaccination programmes in endemic countries have identified the potential significance of surface gene mutants as a cause for failure of immunisation. In the study outlined in this paper, we screened infected children and their mothers for the emergence and prevalence of these variants in specimens collected from the four country evaluation. Although the opportunity for the emergence of HBV vaccine escape mutants in these populations was high due to the presence of a considerable amount of the virus in the population and the selection pressure from vaccine use, there were no a determinant vaccine escape mutants found. This suggests that vaccine escape variants are not an important cause for failure to prevent HBV transmission in this setting. Other HBsAg variants were detected, but their functional significance remains to be determined. The failure to provide satisfactory protection during such immunisation programmes reflects the need for achieving and sustaining high vaccine coverage, improving the timeliness of doses as well as improving 'cold-chain' support, rather than the selection of vaccine-escape mutants of HBV. (C) 2004 Elsevier Ltd. All rights reserved.

HBsAg seroclearance or seroconversion induced by peg-interferon alpha and lamivudine or adefovir combination therapy in chronic hepatitis B treatment: a meta-analysis and systematic review

Background and aims: Seroclearance or seroconversion of hepatitis B surface antigen (HBsAg) is generally considered as a clinical endpoint. The purpose of the present meta-analysis was to evaluate the effect of combined therapy with pegylated interferon alpha (PEG-IFNα) with or without lamivudine (LAM) or adefovir (ADV) on HBsAg seroclearance or seroconversion in subjects with chronic hepatitis B (CHB). Methods: Randomized controlled trials performed through May 30th 2015 in adults with CHB receiving PEG-IFNα and LAM or ADV combination therapy or monotherapy for 48-52 weeks were included. The Review Manager Software 5.2.0 was used for the meta-analysis. Results: No statistical differences in HBsAg seroclearance (9.9% vs. 7.1%, OR = 1.47, 95% CI: 0.75, 2.90; p = 0.26) or HBsAg seroconversion (4.2% vs. 3.7%, OR = 1.17, 95% CI: 0.57, 2.37; p = 0.67) rates were noticed between PEG-IFNα + LAM and PEG-IFN α + placebo during post-treatment follow-up for 24-26-weeks in subjects with hepatitis Be antigen (HBeAg)-positive CHB. No statistical differences in HBsAg clearance (10.5% vs. 6.4%, OR = 1.68, 95% CI: 0.75, 3.76; p = 0.21) were seen, but statistical differences in HBsAg seroconversion (6.3% vs. 0%, OR = 7.22, 95% CI: 1.23, 42.40; p = 0.03) were observed, between PEG-IFNα + ADV and PEG-IFNα for 48-52 weeks of treatment in subjects with HBeAg-positive CHB. A systematic evaluation showed no differences in HBsAg disappearance and seroconversion rates between PEG-IFNα + placebo and PEG-IFNα + LAM for 48-52 weeks in subjects with HBeAg-positive CHB. A systematic assessment found no differences in HBsAg disappearance and seroconversion rates between PEG-IFNα + placebo and PEG-IFNα + LAM during 24 weeks' to 3 years' follow-up after treatment in subjects with HBeAg-negative CHB. Conclusion: Combined therapy with PEG-IFNα and LAM or ADV was not superior to monotherapy with PEG-IFNα in terms of HBsAg seroclearance or seroconversion.

Detection of hepatitis B virus markers using a biosensor based on imaging ellipsometry

A biosensor based on imaging ellipsometry (BIE) has been developed and validated in 169 patients for detecting five markers of hepatitis B virus (HBV) infection. The methodology has been established to pave the way for clinical diagnosis, including ligand screening, determination of the sensitivity, set-up of cut-off values (CoVs) and comparison with other clinical methods. A matrix assay method was established for ligand screening. The CoVs of HBV markers were derived with the help of receiver operating characteristic curves. Enzyme-linked immunosorbent assay (ELISA) was the reference method. Ligands with high bioactivity were selected and sensitivities of 1 ng/mL and 1 IU/mL for hepatitis B surface antigen (HBsAg) and surface antibody (anti-HBs) were obtained respectively. The CoVs of HBsAg, anti-HBs, hepatitis B e antigen, hepatitis B e antibody and core antibody were as follows: 15%, 18%, 15%, 20% and 15%, respectively, which were the percentages over the values of corresponding ligand controls. BIE can simultaneously detect up to five markers within 1 h with results in acceptable agreement with ELISA, and thus shows a potential for diagnosing hepatitis B with high throughput.

含双向乙肝表面抗原基因的重组质粒的构建和表达

将含有一个HBsAg基因的表达质粒经过修饰后作为起始质粒，构建了含双向HBsAg基因的表达质粒pGJP2S。其中两个HBsAg基因均受痘苗病毒7.5K基因起动子的控制，但是方向相反。用该质粒和野生型痘苗病毒共转染CV-1细胞，可导致HBsAg的合成和分泌。该双向质粒可用于研究双向HBsAg基因对HBsAg表达水平的影响。

Rapid optimization of process conditions for cultivation of transgenic Laminaria japonica gametophyte cells in a stirred-tank bioreactor

Batch cultivation for transgenic kelp gametophyte cells was investigated in an online controlled 5 L stirred-tank photo-bioreactor to rapidly optimize the process conditions by monitoring the rate of increase of pH. The transgenic kelp gametophytes with heterologous gene encoding hepatitis B surface antigen (HBsAg) could rapidly grow in the bioreactor. Optimal temperature and agitation rate for bioreactor cultivation of gametophytes were 15 degrees C and 200 rpm. Optimal incident light intensities depended on the initial cell densities. (c) 2006 Elsevier B.V. All fights reserved.

转基因海带配子体的制备与高效增殖

海带具有很高的营养价值和经济社会价值。自20世纪90年代以来，本实验室在借鉴高等植物基因工程原理和方法的基础上，根据海带自身特点，建立了海带遗传转化体系（海带孢子体表达系统），它的基本原理是利用基因枪法转化海带配子体，经孤雌或受精途径再生幼孢子体后，用氯霉素筛选幼孢子体获得转基因海带，然后进行海上安全栽培和转基因产品的检测与提取。目前该表达系统已成功实现报告基因（β-半乳糖苷酶基因，lacZ）和功能基因（乙肝表面抗原基因，HBsAg）的稳定表达。 由于海带孢子体表达系统需经孢子体再生和海上栽培等阶段，周期较长，而且转基因安全性问题也在一定程度上制约其研究与应用。因此，我们在海带孢子体表达系统的基础上又建立和优化了海带配子体表达系统，并成功实现了报告基因（绿色荧光蛋白基因，GFP）的瞬间表达和功能基因（瑞替普酶基因，rt-PA）的稳定表达。虽然海带配子体表达系统能避免转基因安全性问题，周期较短，但在表达量和生物量积累方面，与孢子体表达系统相比还有较大差距。 本文首先在海带配子体表达系统中成功实现了人酸性成纤维细胞生长因子基因（hafgf）和鲎素基因（tac）的稳定表达，制备了转基因海带配子体，然后将光生物反应器培养技术应用于转基因海带配子体的高效增殖，以期解决阻碍海带配子体表达系统发展的量的问题，并为转基因海带配子体的大规模培养提供试验依据和技术支持。 本文的研究结果为： 1、人酸性成纤维细胞生长因子基因和鲎素基因可以稳定整合到海带配子体基因组中，实现转基因产物的表达。 2、根据转基因海带配子体的生长特点，研制开发了一套培养体积为300 ml的鼓泡式光生物反应器，它具有操作简便、成本低廉、适合海带配子体生长等特点。随后将培养体系扩大到2.5 L，并研究了光对转基因海带配子体生长的影响，试验结果显示，转基因海带配子体在光强为30 μE m-2 s-1时即可达到光饱和生长，最优光周期为14:10 LD，而且蓝光可促进转基因海带配子体的生长。 3、在前期研究工作的基础上，为改善反应器内的传质条件，我们又设计研制了2.5 L气升式光生物反应器用于转基因海带配子体的高效增殖。研究发现，气升式光生物反应器较鼓泡式光生物反应器能明显地改善反应器内的传质状态，实现转基因海带配子体更高密度的培养（生物量可达到1,990 mg L-1），是一套高密度悬浮培养转基因海带配子体的有效装置和设备。

利用海带配子体营养增殖体系实现外源基因表达

1993年以来，本实验室在借鉴高等植物基因工程原理和方法的基础上，利用海带世代交替生活史，建立了海带遗传转化体系,并申请国家专利PCT/CN03/00534（Trends in Biotechnology, 2005, 23,264-268.）。海带遗传转化体系是建立在基因枪转化海带配子体，经孤雌或受精途径再生幼孢子体后用氯霉素筛选以及海上安全栽培等一系列技术平台上的新型体系。目前该体系已经成功实现报告基因（β-半乳糖甘酶基因，LacZ）和目的基因（乙肝表面抗原基因，HBsAg）在孢子体阶段的稳定表达。由于应用该体系表达目的基因须经过孢子体再生以及海上栽培等阶段，周期较长，因此本论文拟通过以下5方面工作初步建立以配子体营养增殖为基础的新型海带表达体系，并尝试在配子体阶段实现转化、筛选、增殖及产物检测等操作。1)确立针对配子体的选择标记。2)利用光生物反应器增殖配子体。3)拓展新的报告基因种类。4)克隆内源高效启动子。5)利用该体系表达rt-PA基因（编码价格昂贵的特效溶栓药，瑞替普酶）。本论文研究结果为1)升高温度能够显著增强草丁膦的筛选效果，根据敏感性实验统计结果确定了草丁膦作为海带配子体遗传转化选择压力的筛选方案为40mg/l连续处理7d×3次。2)利用室内光生物反应器营养增殖海带配子体技术，经草丁膦筛选，实现了SV40启动子驱动草丁膦抗性基因bar在配子体细胞中的稳定表达。3)采用调整配子体营养生长状态的方法减低背景荧光，从而首次观察到增强型绿色荧光蛋白基因（egfp）在海带配子体细胞中的瞬间表达。4)克隆了海带肌动蛋白基因（actin）的基因组序列，这是褐藻肌动蛋白基因组序列克隆的首次报道，通过染色体步移获得海带actin基因上游约450bp的片段。5)在上述工作基础上，与中国药科大学合作构建了瑞替普酶基因（rt-PA）的海带表达载体，并实现该基因在海带配子体细胞中的稳定表达，产物具有正确的生物学活性，平均表达量达到0.159μg/mg可溶蛋白。这是该基因在植物中表达的首次报道。研究结果提示在光生物反应器营养增殖体系基础上构建海带配子体表达系统的方案是可行的。

Preparation and a time-resolved fluoroimmunoassay application of new europium fluorescent nanoparticles

New silica-based europium fluorescent nanoparticles having surface amino groups were prepared by a covalent binding-copolymerization technique. In the nanoparticles, the fluorescent Eu3+ chelate molecules were covalently bound to silicon atoms to protect the nanoparticles from dye leaking in bio-applications. The amino groups on the surface of nanoparticles made the surface modification and bioconjugation of nanoparticles easier. The nanoparticles were characterized and developed as a new type of fluorescence probe for a highly sensitive time-resolved fluoroimmunoassay (TR-FIA) of human hepatitis B surface antigen (HBsAg).

Veterans health administration hepatitis B testing and treatment with anti-CD20 antibody administration.

AIM: To evaluate pretreatment hepatitis B virus (HBV) testing, vaccination, and antiviral treatment rates in Veterans Affairs patients receiving anti-CD20 Ab for quality improvement. METHODS: We performed a retrospective cohort study using a national repository of Veterans Health Administration (VHA) electronic health record data. We identified all patients receiving anti-CD20 Ab treatment (2002-2014). We ascertained patient demographics, laboratory results, HBV vaccination status (from vaccination records), pharmacy data, and vital status. The high risk period for HBV reactivation is during anti-CD20 Ab treatment and 12 mo follow up. Therefore, we analyzed those who were followed to death or for at least 12 mo after completing anti-CD20 Ab. Pretreatment serologic tests were used to categorize chronic HBV (hepatitis B surface antigen positive or HBsAg+), past HBV (HBsAg-, hepatitis B core antibody positive or HBcAb+), resolved HBV (HBsAg-, HBcAb+, hepatitis B surface antibody positive or HBsAb+), likely prior vaccination (isolated HBsAb+), HBV negative (HBsAg-, HBcAb-), or unknown. Acute hepatitis B was defined by the appearance of HBsAg+ in the high risk period in patients who were pretreatment HBV negative. We assessed HBV antiviral treatment and the incidence of hepatitis, liver failure, and death during the high risk period. Cumulative hepatitis, liver failure, and death after anti-CD20 Ab initiation were compared by HBV disease categories and differences compared using the χ(2) test. Mean time to hepatitis peak alanine aminotransferase, liver failure, and death relative to anti-CD20 Ab administration and follow-up were also compared by HBV disease group. RESULTS: Among 19304 VHA patients who received anti-CD20 Ab, 10224 (53%) had pretreatment HBsAg testing during the study period, with 49% and 43% tested for HBsAg and HBcAb, respectively within 6 mo pretreatment in 2014. Of those tested, 2% (167/10224) had chronic HBV, 4% (326/7903) past HBV, 5% (427/8110) resolved HBV, 8% (628/8110) likely prior HBV vaccination, and 76% (6022/7903) were HBV negative. In those with chronic HBV infection, ≤ 37% received HBV antiviral treatment during the high risk period while 21% to 23% of those with past or resolved HBV, respectively, received HBV antiviral treatment. During and 12 mo after anti-CD20 Ab, the rate of hepatitis was significantly greater in those HBV positive vs negative (P = 0.001). The mortality rate was 35%-40% in chronic or past hepatitis B and 26%-31% in hepatitis B negative. In those pretreatment HBV negative, 16 (0.3%) developed acute hepatitis B of 4947 tested during anti-CD20Ab treatment and follow-up. CONCLUSION: While HBV testing of Veterans has increased prior to anti-CD20 Ab, few HBV+ patients received HBV antivirals, suggesting electronic health record algorithms may enhance health outcomes.

Confecção e ampliação do painel sorológico de HTLV

A verificação da qualidade dos kits de diagnóstico para detecção do HTLV-I/II é essencial, uma vez que são utilizados tanto em rotinas laboratoriais como em Serviços de Hemoterapia para aprovar a doação de sangue. Os conjuntos diagnósticos constituem uma ferramenta fundamental para diagnóstico por possuírem uma alta sensibilidade e especificidade, garantindo a confiabilidade dos resultados. Pela variedade de conjuntos diagnósticos encontrados no mercado, é necessário um rigoroso controle de qualidade para evitar possíveis erros analíticos como resultados falso-positivos, causando problemas emocionais e sociais no doador. O presente trabalho foi realizado no intuito de caracterizar unidades de plasma obtidas de Serviços de Hemoterapia de diversas regiões do país para compor e ampliar um painel de referência para HTLV que será utilizado na verificação do controle de qualidade dos kits de diagnóstico para o HTLV-I/II, aumentando a capacidade analítica do Laboratório de Sangue e Hemoderivados (LSH), localizado no Instituto Nacional de Controle de Qualidade em Saúde (INCQS)/Fiocruz. Desta forma, foram analisadas no período de 2000 a 2013, 3.559 unidades de plasma. Das unidades que foram encaminhadas para o INCQS, 109 foram enviadas como reagentes para HTLV, sendo recaracterizadas pela triagem de marcadores para HIV-1/2, hepatite C, HBsAg, anti-HBc, Doença de Chagas e Sífilis. A princípio foram realizados dois testes para HTLV-I/II. As unidades de plasma com reatividade apenas para anti-HTLV-I/II foram testadas através da técnica de ELISA e nas amostras com resultado reativo, a confirmação foi realizada por Western Blot. Todos os testes realizados seguiram rigorosamente as técnicas descritas nos manuais de instrução de cada fabricante. Por fim, foram obtidas76 amostras com reatividade para anti-HTLV-I/II, possibilitando a ampliação do painel de referência já existente no LSH e consequentemente a capacidade analítica do laboratório.

Population-Based Multicentric Survey of Hepatitis B Infection and Risk Factor Differences among Three Regions in Brazil

This multicentric population-based study in Brazil is the first national effort to estimate the prevalence of hepatitis B (HBV) and risk factors in the capital cities of the Northeast. Central-West, and Federal Districts (2004-2005). Random multistage cluster sampling was used to select persons 13-69 years of age. Markers for HBV were tested by enzyme-linked immunosorbent assay. The HBV genotypes were determined by sequencing hepatitis B surface antigen (HBsAg). Multivariate analyses and simple catalytic model were performed. Overall. 7,881 persons were inculded < 70% were not vaccinated. Positivity for HBsAg was less than 1% among non-vaccinated persons and genotypes A, D, and F co-circulated. The incidence of infection increased with age with similar force of infection in all regions. Males and persons having initiated sexual activity were associated with HBV infection in the two settings: healthcare jobs and prior hospitalization were risk factors in the Federal District. Our survey classified these regions as areas with HBV endemicity and highlighted the risk factors differences among the settings.

Household survey of hepatitis B vaccine coverage among Brazilian children

We conducted a multi-stage household cluster survey to calculate hepatitis B vaccine coverage among children 18-30 months of age in 27 Brazilian cities. Hepatitis B vaccine is administered at birth, 1 month and 6 months of age by Brazil`s national immunization program. Among 17,749 children surveyed, 40.2% received a birth dose within one day of birth, 94.8% received at least one dose of hepatitis B vaccine, and 86.7% completed the three-dose series by 12 months of age. Increased coverage with the birth dose and administration of hepatitis B in combination with diphtheria-tetanus-pertussis-Haemophilus influenzae type b antigens could improve protection against hepatitis B. (C) 2009 Elsevier Ltd. All rights reserved.